CN102940675A - Medicine composition for treating cardia-cerebrovascular diseases - Google Patents
Medicine composition for treating cardia-cerebrovascular diseases Download PDFInfo
- Publication number
- CN102940675A CN102940675A CN2012104283053A CN201210428305A CN102940675A CN 102940675 A CN102940675 A CN 102940675A CN 2012104283053 A CN2012104283053 A CN 2012104283053A CN 201210428305 A CN201210428305 A CN 201210428305A CN 102940675 A CN102940675 A CN 102940675A
- Authority
- CN
- China
- Prior art keywords
- parts
- caulis sargentodoxae
- cerebrovascular disease
- radix glycyrrhizae
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title description 9
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 22
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 10
- 241000545442 Radix Species 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 5
- 235000006533 astragalus Nutrition 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 235000011477 liquorice Nutrition 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000501113 Sargentodoxa cuneata Species 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000000284 extract Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000010828 elution Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000012567 medical material Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012891 Ringer solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 4
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 4
- 241000244365 Ligusticum sinense Species 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- -1 transfusion Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine composition for treating cardia-cerebrovascular diseases, comprising Astragalus mongholicus, sargentodoxa cuneata, Ligusticum wallichii, and liquorice. The medicine composition disclosed herein can tonify qi and blood, tranquilize mind and nourish heart, and nourish the kidney and liver, and especially has good curative effect on ischemic cerebrovascular disease.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, relating in particular to a kind of is the medicament that raw material is made by the Radix Astragali, Caulis Sargentodoxae, Rhizoma Chuanxiong and Radix Glycyrrhizae.
Background technology
People's health in the cardiovascular and cerebrovascular disease serious threats such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, learn according to Epidemiological study, the M ﹠ M of cardiovascular and cerebrovascular disease is all in rising trend in recent years, the sickness rate of cardiovascular and cerebrovascular disease is 140-200/10 ten thousand people in the worldwide, its average mortality is 1,00/,100,000 people, has leapt to first of the various diseases at the mortality rate of China's cardiovascular and cerebrovascular disease.In the pathogenic factor of cardiovascular and cerebrovascular disease, atherosclerosis is main cause, and it is the pathogenesis basis of hypertension, coronary heart disease, myocardial infarction, apoplexy cardiovascular and cerebrovascular disease.Suppressing the blood coagulation, improve blood fluidity, is one of key areas of cardiovascular medicament research and development.
In the medicine of cardiovascular and cerebrovascular disease, Chinese medicine and western medicine is all used, and Chinese medicine is little and occupy the larger market share with its toxic and side effects, but its curative effect not rapidly, effective ingredient is not obvious, medication dose is large.
Summary of the invention
Purpose of the present invention just provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can be regulated the flow of vital energy, the effect of promoting blood circulation to remove obstruction in the collateral, more has short medicine to see through the effects such as blood brain barrier, " priming is up " simultaneously, and curative effect is significantly improved.
The technical solution adopted for the present invention to solve the technical problems is:
A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is to be the medicament that raw material is made by the Radix Astragali, Caulis Sargentodoxae, Rhizoma Chuanxiong and Radix Glycyrrhizae.
The weight proportion of the used medicine material of pharmaceutical composition of the present invention can be Radix Astragali 10-20 part, Caulis Sargentodoxae 3-10 part, Rhizoma Chuanxiong 1-6 part, Radix Glycyrrhizae 1-5 part.
The optimum ratio of the used medicine material of pharmaceutical composition of the present invention is: Radix Astragali 12-18 part, Caulis Sargentodoxae 5-8 part, Rhizoma Chuanxiong 2-4 part, Radix Glycyrrhizae 2-4 part.
The raw materials used best proportioning of pharmaceutical composition of the present invention is: 15 parts of the Radixs Astragali, 6 parts of Caulis Sargentodoxae, 3 parts of Rhizoma Chuanxiongs, 3 parts in Radix Glycyrrhizae.
The dosage form of pharmaceutical composition of the present invention can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, the granule.
Pharmaceutical composition of the present invention can be applied to the cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
(1) gets Milkvetch Root by formula proportion, the ethanol of 8-10 times of volume of adding or water reflux, extract, three times, extraction time is respectively 2.0,1.5,1.5h, collects merge extractive liquid, and concentrated, in the extracting solution after concentrated, thin up, staticly settle, filter, get supernatant concentration and become rare extractum, drying obtains Radix Astragali extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, the 70-95% ethanol that adds 8-10 times of volume is heated to 60-80 ℃ and extracts three times, and each 0.5-1h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with the 50-95% alcohol reflux of 8-10 times of volume 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, get extractum, be dissolved in water sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15-1:20), washes with water first, and this water elution liquid is discarded need not, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying gets Rhizoma Chuanxiong extract.
(4) press formula proportion extracting liquorice medical material, add the water boiling and extraction 2 times of 8-10 times of volume, each 1.5-2h, merge extractive liquid,, concentrated, dry, get Radix Glycyrrhizae extract.
(5) the said extracted thing is mixed, make acceptable various pharmaceutical dosage form.
In the pharmaceutical composition of the present invention, Radix Astragali nature and flavor are sweet, warm, return lung meridian, spleen channel, have invigorating QI to consolidate the body surface resistance, inducing diuresis to remove edema, expelling pus and toxin by strengthening QI, the function of expelling pus and promoting granulation.Modern pharmacological research shows that the Radix Astragali has the effect of strengthening contraction to normal heart, and the heart contraction amplitude is increased, and discharges hypervolemia, can improve the left ventricular function of Patients with Viral Myocarditis, also has the effect of certain arrhythmia, blood pressure lowering.
The Caulis Sargentodoxae nature and flavor are flat, bitter; Return large intestine, Liver Channel, have heat-clearing and toxic substances removing, invigorate blood circulation, the function of dispeling the wind.Be used for abdominalgia with intestinal abscess, amenorrhea dysmenorrhea, rheumatic arthralgia, tumbling and swelling.
The Rhizoma Chuanxiong acrid in the mouth is warm in nature, returns Liver Channel, gallbladder meridian, pericardium channel, has the function of blood circulation promoting and blood stasis dispelling, activating QI to alleviate the depression, wind-expelling pain-stopping.Cure mainly: menoxenia; The amenorrhea dysmenorrhea; Puerperal, the stasis of blood stagnated raw meat bitterly; The mass in the abdomen lump; Pain in chest and hypochondrium; Have a headache dizzy; Anemofrigid-damp arthralgia; Traumatic injury; Ulcer sores.Modern pharmacological research shows, Rhizoma Chuanxiong can increase coronary flow, improves the myocardial ischemia situation, prolongs in the platelet aggregation time that external ADP induces, and the platelet of having assembled is had depolymerisation.
The Radix Glycyrrhizae nature and flavor are sweet, flat, and GUIXIN, lung, spleen, stomach warp have the QI invigorating invigorating middle warmer, the function of heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, the mediation property of medicine.
Compared with prior art, the invention has the beneficial effects as follows: pharmaceutical composition of the present invention is comprised of the Radix Astragali, Caulis Sargentodoxae, Rhizoma Chuanxiong and Radix Glycyrrhizae.Radix Astragali invigorating QI to consolidate the body surface resistance, inducing diuresis to remove edema, the people of the suitable deficiency of vital energy; The Caulis Sargentodoxae promoting blood circulation by removing wind; Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain; The Radix Glycyrrhizae sweet in the mouth, the flat coordinating the actions of various ingredients in a prescription of property.The monarch and his subjects help accessory drugs and mutually are in harmonious proportion, and realize inrigorating qi and promoting blood circulation, and the dissipating depression of QI pain relieving makes the QI and blood colleague, and the pathogenesis of " blood stasis due to qi deficiency " just hits; Refining formula, medication four flavor has only reached QI invigorating, has invigorated blood circulation, the effect of dissipating depression of QI, pain relieving, proves that through pharmacodynamics test it is evident in efficacy.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment 1
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Radix Astragali 15g, Caulis Sargentodoxae 6g, Rhizoma Chuanxiong 3g, Radix Glycyrrhizae 3g.
Above-mentioned medicinal raw material is prepared into soft capsule, and preparation method is as follows:
(1) gets Milkvetch Root by formula proportion, 95% alcohol reflux of 10 times of volumes of adding three times, extraction time is respectively 2.0,1.5,1.5h, collects merge extractive liquid, and concentrated, in the extracting solution after concentrated, thin up, staticly settle, filter, get supernatant concentration and become rare extractum, drying obtains Radix Astragali extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 95% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 0.5h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 95% alcohol reflux of 10 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, get extractum, be dissolved in water sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15), washes with water first, and this water elution liquid is discarded need not, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying gets Rhizoma Chuanxiong extract.
(4) press formula proportion extracting liquorice medical material, add the water boiling and extraction 2 times of 8 times of volumes, each 1.5h, merge extractive liquid,, concentrated, dry, get Radix Glycyrrhizae extract.
(5) with said mixture and vegetable oil 25g, mixing is made capsule casing material with gelatin, is pressed into soft capsule.
Embodiment 2
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Radix Astragali 20g, Caulis Sargentodoxae 10g, Rhizoma Chuanxiong 6g, Radix Glycyrrhizae 5g.
Above-mentioned medicinal raw material is prepared into injectable powder, and preparation method is as follows:
(1) gets Milkvetch Root by formula proportion, the water reflux, extract, of 10 times of volumes of adding three times, extraction time is respectively 2.0,1.5,1.5h, collects merge extractive liquid, and concentrated, in the extracting solution after concentrated, thin up, staticly settle, filter, get supernatant concentration and become rare extractum, drying obtains Radix Astragali extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 70% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 1h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 50% alcohol reflux of 10 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, get extractum, be dissolved in water sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:20), washes with water first, and this water elution liquid is discarded need not, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying gets Rhizoma Chuanxiong extract.
(4) press formula proportion extracting liquorice medical material, add the water boiling and extraction 2 times of 8 times of volumes, each-2h, merge extractive liquid,, concentrated, dry, get Radix Glycyrrhizae extract.
(5) said mixture is dissolved in the 1000mL water for injection, filters, adopt existing preparation of injection, make injectable powder.
Embodiment 3
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Radix Astragali 12g, Caulis Sargentodoxae 5g, Rhizoma Chuanxiong 2g, Radix Glycyrrhizae 2g.
Above-mentioned medicinal raw material is prepared into capsule, and preparation method is as follows:
(1) gets Milkvetch Root by formula proportion, the ethanol of 8 times of volumes of adding or water reflux, extract, three times, extraction time is respectively 2.0,1.5,1.5h, collects merge extractive liquid, and concentrated, in the extracting solution after concentrated, thin up, staticly settle, filter, get supernatant concentration and become rare extractum, drying obtains Radix Astragali extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 70% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 1h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get Ligusticum chuanxiong Hort by formula proportion, with 95% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, get extractum, be dissolved in water sucking filtration, filtrate is crossed macroporous resin column (volume ratio of extractum and resin is 1:15), washes with water first, and this water elution liquid is discarded need not, then use 30% ethanol elution, merge 30% ethanol elution, decompression recycling ethanol, vacuum drying gets Rhizoma Chuanxiong extract.
(4) press formula proportion extracting liquorice medical material, add the water boiling and extraction 2 times of 10 volumes, each 2h, merge extractive liquid,, concentrated, dry, get Radix Glycyrrhizae extract.
(5) with said mixture and starch 100g mix homogeneously, adopt capsules preparation technique, make the pharmaceutical composition of capsule.
Test example
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
Test one: the pharmacodynamics test that rat " rabbit brain powder-macromolecule glucosan " is caused the therapeutical effect of cerebral infarction
Principle: because cardiovascular and cerebrovascular disease all can cause hemorheological change, so can design medicine causes the therapeutical effect of cerebral infarction to rat " rabbit brain powder-macromolecule glucosan " pharmacodynamics test, investigate the change of hemorheological property behind the cerebral infarction to measure whole blood viscosity under the different shear rates, investigate erythrocyte deformability with erythrocyte albumen ringer solution viscosity, thereby investigate medicine to the therapeutical effect of cardiovascular and cerebrovascular disease.
Material: animal: rat, body weight 250-350g, male and female half and half.Equipment: cone and plate viscometer, centrifuge, scale centrifuge tube, eye scissors, ophthalmic tweezers and operating theater instruments commonly used, 0 trumpeter's art silk thread, vascular clamp etc.
Medicine and reagent:
15 parts of the test example 1:(Radixs Astragali, 6 parts of Caulis Sargentodoxae, 3 parts of Rhizoma Chuanxiongs, 3 parts in Radix Glycyrrhizae);
20 parts of the test example 2:(Radixs Astragali, 10 parts of Caulis Sargentodoxae, 6 parts of Rhizoma Chuanxiongs, 5 parts in Radix Glycyrrhizae);
12 parts of the test example 3:(Radixs Astragali, 5 parts of Caulis Sargentodoxae, 2 parts of Rhizoma Chuanxiongs, 2 parts in Radix Glycyrrhizae);
15 parts of the Comparative Examples 1:(Radixs Astragali, 6 parts of Caulis Sargentodoxae, 3 parts in Radix Glycyrrhizae);
15 parts of the Comparative Examples 2:(Radixs Astragali, 3 parts of Rhizoma Chuanxiongs, 3 parts in Radix Glycyrrhizae);
Above medicine adopts embodiment 2 to be prepared into test sample.
With the positive medicine contrast of commercially available Breviscapini injection; Rabbit brain powder (rabbit brain powder thromboplastin powder).Get the rabbit brain powder between the sub-sieve 120-150 order, granule is 100-120 μ m.Macromolecule glucosan: molecular weight 5,000,000.The preparation of suppository: the 25mg rabbit brain powder is mixed among the 10% macromolecule dextran solution 100mL, places 37 ℃ of water-baths 40 minutes.Then, be put in-18 ℃ of refrigerators for subsequent use.Rapid Medical ZT glue.BSA, ringer solution.Heparin sodium: press 20u/mL blood dosage and add test tube, 40 ℃ of following dry for standby.
Test method: 1, the rat cerebral infarction model prepares: the rat etherization, lie on the back fixing, and skin cropping sterilization, cervical region cuts, and neck always beats one's brains on the left of separating, neck is interior, external carotid artery.Folder closes external carotid artery, common carotid artery proximal part respectively.Press from both sides again a vascular clamp at the distal end place.After suppository shaken up, lunge common carotid artery with the 0.25mL syringe by 0.03mL/100g rat dosage, open the distal end vascular clamp, suppository is injected.Then, folder closes the common carotid artery distal end, extracts syringe needle, with the bonding pin hole of medical adhesive.Decontrol successively the vascular clamp of common carotid artery distal end, proximal part, external carotid artery after 1 minute, recover blood flow, cleaning wound, skin suture.
Medicine on cerebral infarction after the hemorheology impact of different time: rat is divided into administration group (test example 1-3 group or reference examples 1-3 group+animal model group), normal saline group (normal saline+animal model group), sham operated rats (matched group), every group of 12 rats.Administration group, normal saline group all impose operation technique as stated above, and the sham operated rats operation technique is identical, but not injected plug agent with the physiologic saline for substitute suppository, is injected in internal carotid artery.
The administration group is in front 3 days oral drugs (test example, reference examples) 1.42g/Kg of operation.Positive drug is in front 1 hour intraperitoneal injection of drugs 1.0mg/Kg of operation.The normal saline group is injected commensurability normal saline.Sham operated rats is not injected any medicine.Later on every morning administration 1 time, for three days on end.
The 3rd day after surgery with rat anesthesia (25% urethane 0.3mL/100g body weight, lumbar injection), and the right common carotid artery blood-letting was measured whole blood viscosity under the different shear rates with cone and plate viscometer in 2 hours in the heparin test tube.Again that whole blood is centrifugal with 1500rpm, suck upper plasma.Then use 0.25% bovine serum albumin-ringer solution rinsing erythrocyte three times, centrifugal 10 minutes of each 1500rpm.At last, in vitro be mixed with erythrocyte at scale: albumen is appointed the erythrocyte albumen ringer solution of liquid=6:4, measures its viscosity at 20 seconds under 1 shear rate.With erythrocyte albumen ringer solution viscosity as erythrocyte deformability.All experiments are all carried out under 25 ℃ of constant temperature, and experimental result is carried out statistical test.Concrete numerical value and the results are shown in Table one.
Table one: on the whole blood viscosity impact (unit: mPa.s) of different time behind the rat cerebral infarction
Annotate: all compare with the normal saline group * * P＜0.05***P＜0.01.
By table one result of the test as can be known, when blocking 3 days, the normal saline group is compared with sham operated rats, whole blood viscosity rising (P＜0.05), animal model modeling success is described, each administration group all can reduce whole blood viscosity to some extent, and wherein with the application's effect of drugs best (P＜0.01), the control drug effect is taken second place.With normal saline group ratio, whole blood viscosity descends, and statistical procedures has significant.
Claims (4)
1. pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that it is is the medicament that raw material is made by the Radix Astragali, Caulis Sargentodoxae, Rhizoma Chuanxiong and Radix Glycyrrhizae.
2. treatment cardiovascular and cerebrovascular disease according to claim 1 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are Radix Astragali 10-20 part, Caulis Sargentodoxae 3-10 part, Rhizoma Chuanxiong 1-6 part, Radix Glycyrrhizae 1-5 part.
3. treatment cardiovascular and cerebrovascular disease according to claim 2 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are Radix Astragali 12-18 part, Caulis Sargentodoxae 5-8 part, Rhizoma Chuanxiong 2-4 part, Radix Glycyrrhizae 2-4 part.
4. treatment cardiovascular and cerebrovascular disease according to claim 3 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are 15 parts of the Radixs Astragali, 6 parts of Caulis Sargentodoxae, 3 parts of Rhizoma Chuanxiongs, 3 parts in Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428305.3A CN102940675B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428305.3A CN102940675B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940675A true CN102940675A (en) | 2013-02-27 |
| CN102940675B CN102940675B (en) | 2014-11-26 |
Family
ID=47723735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210428305.3A Expired - Fee Related CN102940675B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940675B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367618A (en) * | 2014-11-10 | 2015-02-25 | 成都果睿医药科技有限公司 | Fructus choerospondiatis-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN104474210A (en) * | 2014-12-12 | 2015-04-01 | 曹勇 | Traditional Chinese medicine composition for treating unstable angina pectoris caused by qi stagnation and blood stasis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262942A (en) * | 1999-01-30 | 2000-08-16 | 赫炎光 | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method |
| CN101168042A (en) * | 2007-11-07 | 2008-04-30 | 周鲁菲 | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method |
-
2012
- 2012-10-31 CN CN201210428305.3A patent/CN102940675B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262942A (en) * | 1999-01-30 | 2000-08-16 | 赫炎光 | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method |
| CN101168042A (en) * | 2007-11-07 | 2008-04-30 | 周鲁菲 | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 张流秀: "黄治品望舌下络脉治疗心脑血管疾病经验", 《世界中医药》 * |
| 潘洪等: "杨思进教授辨治心衰血瘀证经验", 《四川中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367618A (en) * | 2014-11-10 | 2015-02-25 | 成都果睿医药科技有限公司 | Fructus choerospondiatis-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN104474210A (en) * | 2014-12-12 | 2015-04-01 | 曹勇 | Traditional Chinese medicine composition for treating unstable angina pectoris caused by qi stagnation and blood stasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940675B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940675B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940668B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN101152243B (en) | Traditional Chinese medicine for treating apoplexy and technique of preparing the same | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102940680B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN101987112B (en) | Medicine composition for treating cardio-cerebrovascular diseases and preparation method thereof | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN103301338A (en) | Traditional Chinese medicine preparation for treating hemophilia and preparation method thereof | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN111558019B (en) | Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, regulating menstruation and relieving pain and preparation method and application thereof | |
| CN102940658A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940676B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104367630A (en) | American ginseng-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN102008623A (en) | Traditional Chinese medicine preparation for treating Meniere's syndrome | |
| CN102940694B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN100415241C (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
| CN104367656A (en) | Hawthorn leaf-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN102940702B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN101664433B (en) | Antitubercular injection and preparation method thereof | |
| CN106389702A (en) | Traditional Chinese medicine for recovering symptoms of gynecological and obstetric surgery and preparation method of traditional Chinese medicine | |
| CN106729101B (en) | Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 |